

Thyroid Status Among HIV Infected Cases Attending ART Centre JNIMS And Correlation Between TSH(US) And CD4Count

Suchitra Chongtham¹, Narmada Thongam², LamabamChanchan Chanu³,
Rosyka Laithangbam⁴, Sujeeta Oinam⁵, KhLokeshwar Singh⁶

¹Associate Professor, Department of Biochemistry, JNIMS, Manipur, India

²Assistant Professor, Department of Biochemistry, JNIMS, Manipur, India

³Assistant Professor, Department of Biochemistry, JNIMS, Manipur, India

⁴PGT, Department of Biochemistry, JNIMS, Manipur, India

⁵PGT, Department of Biochemistry, JNIMS, Manipur, India

⁶Associate Professor, Department of Medicine, JNIMS, Manipur, India

*Correspondence:Dr. Narmada Thongam

Date of Submission: 14-08-2019

Date of Acceptance: 30-08-2019

I. Introduction

There is some evidence to suggest an increasing number of patients taking ART drugs are presenting with thyroid disorders. Thyroid hormone plays a fundamental role in metabolism and regulate immune system¹. HIV infection involves almost all the organs and systems including endocrine glands. So an alteration in the thyroid function is possible if not directly by the virus itself^{2,3}. Specific pattern of abnormal TFT findings are more frequently identified among HIV infected patients although the prevalence of overt thyroid disease does not appear to be significantly increased in HIV infected patients compared with general population.⁴ Discrepancy remains in the prevalence rate of thyroid dysfunction reported from India and abroad. There is still a lack of a concrete evidence of thyroid dysfunction in patients on ART and also with the duration of the disease. Owing to the paucity of data of thyroid study in HIV cases on ART, this study was conducted in northeastern part of the country with an objective to find out the thyroid status among HIV positive cases attending ART centre JNIMS and also to find out correlation, if any, between ultrasensitive TSH(usTSH) and CD4 count.

II. Materials and methods

This cross sectional study was conducted at ART Centre JNIMS Hospital, a tertiary care centre at Imphal, Manipur on a cohort of 191 confirmed HIV positive cases in the age group 18 years and above, irrespective of sex, caste, creed or religion. Eligible HIV confirmed cases attending ART centre JNIMS were randomly selected and enrolled for the study during the period between March 2015-September 2015 after taking written informed consent.

A detailed clinical history of the covariates including route of infection, duration from the time of diagnosis of HIV, duration on ART drug intake, any untoward incident, drugs reaction etc. was recorded, along with which a detailed clinical examination was done in each subject.

Exclusion criteria: Acutely ill, Hepatitis B, C coinfections, pregnant women, Diabetes mellitus, cases with previous history of thyroid dysfunction or drug intake were excluded from the study.

Ethical statement : Ethical clearance from institutional ethical committee, JNIMS was obtained prior to the onset of the study.

After taking due informed consent 5 ml of fasting venous blood was collected from ante-cubital vein after taking aseptic and antiseptic precautions between 8-10 AM. Out of the total blood volume collected 2.5 ml was separated in K₂EDTA vacutainer and sent for CD4 count. Serum was separated later from the remaining 2.5 ml and thyroid hormones free T₃(fT₃), free T₄(fT₄) and ultrasensitive usTSH were analysed on the same day.

Thyroid function was assessed by measuring serum free T₃(fT₃), free T₄(fT₄), and ultra sensitive TSH(usTSH) by quantitative ELISA method using Benesphera and DRG kits in Biochemistry Department JNIMS. As per the manufacturer's protocol the normal ranges of usTSH, fT₃ and fT₄ were (0.54- 4.72) μ IU/ml, (1.4 -4.2) pg/ml and (0.8-2.0) μ g/dl respectively. Thyroid disorders were categorized as

hyperthyroidism(overproduction of T3 and T4) and hypothyroidism (underproduction of T3,and T4).Hypothyroidism was further categorized as overt (high TSH,low T4) and subclinical (high TSH,normal T4)and low ft4 (normal TSH and ft4<1.4 pg/ml).Similarly hyperthyroidism was categorized as subclinical (TSH<- 0.3 µIU/ml, normal ft4) and overt hyperthyroidism(TSH<- 0.3 µIU/ml,ft4>4.2 pg/ml).This classification is based as per the report published by Beltran S et al.⁵

Other routine test parameters like Serum Alanine transaminase(ALT) and Aspartate transaminase(AST) were measured with kinetic method with pyridoxal-5 phosphate(LDH/NADH)and pyridoxal-5phosphate(visible method) respectively,in Vitros-250 dry chemistry autoanalyzer.Blood urea was determined by urease with indicator dye method, serum creatinine by enzymatic(creatinineamiohydrolase) method in the same machine

Blood CD4 count was done by flow cytometry, Beckton Dickenson fluorescent activated cell sorter (FACS) machine in Microbiology Department,JNIMS.Hemoglobin was done in automated hematological counter in Pathology department.

III. Results

A total of 191 retro reactive patients on Anti Retro Viral Therapy (ART), attending ART Centre JNIMS were selected in a random manner.The data collected was fitted into microsoft excel format and analysed using SPSS version 21.

The study parameters were expressed as mean ±SD,median, percentage(%).Karl Pearson’s correlation test was applied to find correlation (r) between the clinical parameters and the statistical significance level of the tests was taken at Probability value P < 0.05.

Out of the total study group majority120 (62.8%) were females and 71(37.2%) were males and most of them were married.The average age of the subjects was 40(±8.8) with a median age of 40 years .Mean weight of the subjects was 53.5±8.1 kg with a maximum of 71 kg and minimum of 27 kg ,Mean Hemoglobin was12.1 (1.4)gm%.The average CD4 count level was446.2(207.9)/cumm ranging from 42/mm³ to 1110/ mm³ .

Serum ALT and AST were 49.1(31.1)U/l and 43.5(33.8)U/l respectively. Average blood urea and creatinine levels were 2.8(7.1) mg/dl and 0.91(1.4) mg/dl respectively.

Thyroid hormones ft3,ft4, and usTSH assays measured an average of 2.19(0.55)pg/ml,1.24(0.32) µg/dl and 2.1(1.75) µIU/ml respectively.

Variable	Parameter Mean±SD	Median	Minimum	Maximum
Weight (Kg)	53.3±8.1	54	27	71
Hb (gm%)	12.1(1.4)	12	7	16
CD4 (per cumm)	446.2(207.9)	443	42	1110
AST(U/L)	43.5(33.8)	35	10	282
ALT(U/L)	49.1(31.1)	42	13	260
Urea(mg/dl)	22.8(7.1)	22	1	78
Creatinine (mg/dl)	0.91(1.4)	0.8	0	21
ft3(pg/ml)	2.19(0.55)	2.1	0.8	4.0
ft4(µg/dl)	1.24(0.32)	1.2	0.0	2.8
usTSH(µIU/ml)	2.10(1.75)	1.6	0.2	8.1
Duration (yr)	5.94(2.75)	6.3	0	11.0

Table1: Showing Mean(SD) of recorded variables of the cases (N=191)

Out of 191 subjects majority 165(86.4%) were euthyroid. Among the thyroid dysfunctions 17 (8.9%) were subclinical hypothyroid with only 2(1%) overt hypothyroid cases.There were 5 (2.6%) subclinical hyperthyroid cases and 2(1.0%) overtly hyperthyroid cases.

Thyroid profile	Number	Percentage (%)
Normal	165	86.4
Subhypo	17	8.9
Hypo	2	1.0
Subhyper	5	2.6
Hyper	2	1.0

Table 2: distribution of subjects according to their thyroid status

When Karl Pearson’s correlation test was applied between CD4 and clinical parameters a significant negative correlation was shown between CD4 and ALT (r = - 0.154) with(P value = 0.033)but correlation between CD4 and AST(r= - 0.120) was not significant(r = - 0.099); CD4 and blood urea (r= - 0.159); (P = 0.028)whereas a positive correlation was observed between CD4 and Hb (r = 0.177) with a P value = 0.015 which is significant

Parameters	Number	Pearson's correlation coefficient (r)	p-value
fT3 (pg/ml)	191	0.001	0.991
fT4 (ug/dl)	191	0.012	0.868
usTSH (uIU/ml)	191	0.052	0.479
AST (U/L)	191	-0.120	0.099
ALT(U/L)	191	-0.154	0.033*
Urea mg/dl	191	-0.159	0.028*
Creatininemg/dl	191	-0.133	0.066
Hb(gm%)	191	0.177	0.015*

Table 3: Pearson's Correlation test between clinical parameters with CD4 level

Parameters	Number	Pearson's correlation coefficient (r)	p-value
fT3	191	-0.002	0.975
fT4	191	0.121	0.095
usTSH	191	0.059	0.414
CD4	191	0.137	0.059
AST	191	0.038	0.600
ALT	191	0.034	0.643
Urea	191	-0.071	0.327
Creatinine	191	0.110	0.130
Hb(gm%)	191	0.112	0.123

Table 4: Pearson's Correlation between clinical parameters with duration of treatment (years)

On an average the subjects in the study group were on ART for 5.94(2.75) years (Table.4). A negative correlation ($r = -0.002$) was observed between fT3 and duration (years) of treatment with ART. Blood urea level also had a negative correlation ($r = -0.071$) with the duration of therapy. In both the cases statistical significance was not detected $P > 0.05$.

Whereas minimal positive correlation was seen between fT4, usTSH, CD4, ALT, AST, Creatinine and Hb with the duration on ART they were all statistically insignificant with $P > 0.05$

IV. Discussion

The subjects in the study had been on ART for varying period of time including those who had taken for only few months. There was a female predominance reflecting transmission from their spouse. The CD4 count of most cases were in the range (401-500)/mm³ and were clinically stable and asymptomatic

HIV infection may cause adaptive changes in thyroid functions and often do not require treatment. Non specific signs and symptoms of thyroid dysfunction may overlap with non endocrine disorders which are common in HIV infected patients. Moreover some medications used to treat HIV infection and its complications can induce thyroid dysfunction.⁶

The female predominance in the study group could be a reflection of onward transmission from their male counterpart. The high mean age 40(+ - 8.8) years of the subjects may be due to HAART increasing the longevity of survival. The average CD4 count of the subjects was 446.2(207.9)/mm³ with a median value of 443mm³, most of them being clinically stable and asymptomatic.

In our study out of 191 cases only 13.5 % of them had thyroid dysfunction. Within this group subclinical hypothyroidism existed in 17(8.9 %) cases and overt hypothyroidism prevailed in just 2(1%) cases. Whereas 5(2.5 %) cases of subclinical hyperthyroid were detected only 2(1%) cases were overtly hyperthyroid.

This prevalence finding of subclinical hypothyroidism closely tallies with that of Rajendra Kumar et al.⁷ with 12% subclinical hypothyroid cases although their number of overt hypothyroidism (6%) outnumbered that in our study (1%). The overall thyroid dysfunction in our study was (13.5%) as compared to theirs with (20%). According to Madeddu G et al.⁸ thyroid abnormalities, mostly subclinical hypothyroidism were associated with HAART therapy particularly Stavudine. Our findings are also comparable to that of Beltran et al.⁵ with 16% cases out of 350 HIV patients having subclinical hypothyroidism and (2.6%) overt hypothyroidism. Similar figure was observed by Sharma et al.⁹ where (14.76%) out of 359 HIV cases were hypothyroid and (5.29%) were having sick euthyroid syndrome.

In contrast to these a much higher and alarming figure was found in a study by Dev N et al where the prevalence of thyroid dysfunction was 75.5% of which 53% were having subclinical hypothyroidism. In a Spanish study by Collazos et al.¹¹ (3.5%) had subclinical hypothyroidism which correlated with low CD4 count but no significant correlation was found between hypothyroidism and CD4 in our study. There was (2.6%) subclinical hyperthyroid but only (1%) overt hyperthyroid cases. This is in near agreement with findings of Madge et al.¹² with (<1%) hyperthyroid case.

In our study there was negligible correlation observed between CD4 count and thyroid hormones fT3, fT4, and TSH which were statistically insignificant. A similar observation was made by Surjit Kumar Tripathy et al.¹³ Contrary to this statement, Meena LP et al.¹⁴ found an elevation of TSH when CD4 count was <200/cumm.

Jain G et al.¹⁵ reported that abnormal thyroid level correlated with CD4 count and severity of disease. Another study by Collazos¹¹ also found a low fT4 level (1.3%) and subclinical hypothyroidism (3.5%) which correlated with low CD4 count.

A negative correlation was found between CD4 count and ALT and AST but significance was found only with ALT. A tendency of ALT to increase with lowering of CD4 was seen. A similar observation of higher liver enzyme abnormality in both ART experienced and ART naïve HIV-1 infected patients was made by Melashu et al.¹⁶ Based on the grading of hepatotoxicity¹⁷ only 10.5 % of our subjects on ART had grade I hepatotoxicity (AST, ALT level >1.25-2.5 X UNL) and 4.1 % were having grade II hepatotoxicity (2.6-5 X UNL) and none of them had severe grades as most of them were clinically stable. The prevalence of liver enzyme abnormalities in this study was 14.6% when compared to (20%) in other studies by Melashu BS et al.¹⁶, Cameroon ((22.6%)¹⁸, South Africa (23%)¹⁹, Brazil (19.7%)²⁰. However the prevalence was lower in (11%) in the general population of Australia.¹⁷

As the duration on ART increases serum ALT, AST tend to rise. The elevated liver enzymes in HIV infected patients might be due to inflammation of hepatocytes by HIV through apoptosis, mitochondrial dysfunction and permeability alteration in mitochondrial membrane that stimulates an inflammatory response^{21,22,23,24}. Adverse drug reactions due to HAART are common ranging from mild to life threatening conditions. They usually occur within first 6-12 weeks but metabolic toxicities happen following prolonged use of antiretroviral therapy.

The observed negative correlation between blood urea and duration on ART could be a slight reflection of lowering metabolic activity of liver in synthesizing urea but a coexisting kidney dysfunction could be ruled out by serum creatinine level and other early markers in suspicious cases.

V. Conclusion

Although thyroid dysfunction is believed to be more common among HIV-infected patients on ART, in our study we found negligible correlation between CD4 count and thyroid hormones fT3, fT4 and TSH. It was also found that thyroid dysfunction had poor correlation with duration of ART even though thyroid hormone abnormalities, predominantly subclinical hypothyroidism were encountered in some cases of the study population. Serum liver enzymes ALT, AST, blood urea, creatinine, Hb levels need to be regularly checked in patients on ART. In spite of the above findings, thyroid function testing from time to time cannot be overlooked until it is substantiated by a well designed longitudinal study on a larger sample size.

References

- [1]. Fabris N, Muzzioli M, Mocchegiani E. Recovery of age dependent, immunological deterioration in Balb/c mice by short term treatment with l-thyroxin. *Mech. Ageing dev.* 1982;8:pp 327-338
- [2]. Raffi F, Brisseau JM, Planchon B et al. Endocrine function in 98 HIV-infected patients: a prospective study. *AIDS* 1991;5:pp, 729-33
- [3]. Dobs AS, Dempsey MA, Ladenson PW et al. Endocrine disorders in men infected with human immunodeficiency virus. *American journal of Medicine*, 1988;84:pp 611-16
- [4]. Christopher J. Hoffmann and Todd T. Brown. Thyroid Function Abnormalities in HIV-Infected Patients. *Clinical Infectious Diseases* 2007;45:488-494
- [5]. Beltran S, Lescure FX, Desailly R et al. Increased prevalence of hypothyroidism among human immunodeficiency virus-infected patients: a need for screening. *Clin Infect Dis*, 2003;37:579-83
- [6]. Melissa Weinberg, MD, Morris Schambelan, MD. Thyroid gland dysfunction in HIV infected patient. Oct 23, 2017. <http://www.uptodate.com>
- [7]. Rajendra Kumar Verma, Richa Giri, Chirag Gupta, Vaibhava Shrivastava, Study of thyroid profile in seropositive HIV adult patients HAART on regimen. *International Journal of Advances in Medicine* .2017;4(4):1092-1098
- [8]. Madeddu G, Spanu A, Chessa F, Callia GM, Lovigu C, Solinas P et al. Thyroid dysfunction in human immunodeficiency virus patients treated with highly active antiretroviral therapy. *Clin. Endocrinol (Oxf)*, 2006;64:375-383
- [9]. Sharma N, Sharma LK, Dutta D, Gadpayle AK, Anand A, Gaurav K, Mukerjee S, Bassal R. Prevalence and Predictors of Thyroid Dysfunction in Patients with HIV Infection and Acquired Immunodeficiency Syndrome: An Indian Perspective. *J Thyroid Res*. 2015;517173, Epub 2015 Dec 22
- [10]. Dev N, Sahoo R, Kulshreshtha B, Gadpayle AK, Sharma SC. Prevalence of thyroid dysfunction and its correlation with CD4 count in newly diagnosed HIV positive adults—a cross sectional study. *Int J STD AIDS*, 2015;26:965-970
- [11]. Collazos J, Ibarra S, Mayo J. Thyroid hormones in HIV infected patients in the highly active antiretroviral era: evidence of an interrelationship between the thyroid axis and the immune system. *AIDS*, 2003;17: pp 763-765
- [12]. Madge S, Smith S, Lampe F, Thomas M, et al : No association between HIV disease and its treatment and thyroid function. *HIV Med* 2007;8(1):22-27
- [13]. Sujit Kumar Tripathy, Ritesh Kumar Agrawala, Anoj Kumar Baliarsingha, Endocrine alterations in HIV-infected patients. *Indian Journal of Endocrinology and Metabolism*, 2015; Vol 19(1):143-147
- [14]. Meena LP, Rai M, Singh SK, Chakravarty J, Singh A, Goel R, Pathak A, Shyamsunder, Endocrine Changes in Male HIV Patients. *JAPI*, 2011;59
- [15]. Jain G, Devpura G, Gupta BS. Abnormalities in thyroid function tests as surrogate markers of advancing HIV infection in infected adults. *JAPI*:2009;57:508-510

- [16]. MelashuBS, KetemaTafessTulu, AmtatachewMogesZegeye and AmarechAsratieWubante. Liver enzyme abnormalities among Highly Active Antiretroviral Therapy Experienced and HAART naïve HIV- Infected patient at Debre Tabor Hospital, North West Ethiopia: A comparative Cross sectional study. *AIDS Research and Treatment* Volume 2016, Article ID 1985452, 7 pages. <http://dx.doi.org/10.1155/2016/1985452>
- [17]. Federal HIV/AIDS Prevention and Control office and Federal Ministry of Health, Guidelines for management of opportunistic infections and Antiretroviral treatment in Adolescents and Adults in Ethiopia, Part I, 2007, <http://www.who.int/hiv/pub/guidelines/Ethiopia>
- [18]. A.C.M.Gil, R.Lorenzetti, G.B.Mendes et al., "Hepatotoxicity in HIV-infected children and adolescents on antiretroviral therapy", *San Paulo Medical Journal*, Vol 125, no. 4, pp. 205-209, 2007. View at Google Scholar, View at Scopus.
- [19]. C.J.Hoffman, S.Charalambous, L.Lithioetal, "Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B", *AIDS*, vol. 21 no. 10, pp. 1301-1308, 2007. View at Publisher, View at Google Scholar, View at Scopus
- [20]. K.Lucent, A.Clement, N.Fon, P.Weldji and C Ndikeu, "The effects of antiretroviral treatment on liver function enzymes among HIV infected outpatients attending the central hospital of Yaoundi Cameroon", *African Journal of Clinical and Experimental Microbiology*, Vol II, no. 3, pp. 174-178, 2010. View at publisher, view at Google Scholar
- [21]. S.Pol, P.Lebray and A.Vallet-Pichard "HIV infection and Hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms", *Clinical Infectious Diseases*, Vol 38, supplement 2, pp. S65-72, 2004. View at Publisher, View at Google Scholar, View at Scopus
- [22]. H.Cote, Z.L.Brumme, K.J.Craib et al., Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients, *The New England Journal of Medicine*, 2002; Vol. 346(11): 811-820. View at publisher, view at Google Scholar
- [23]. E.Jacotot, L.Ravagnan, M.Loeffler et al., The HIV -1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. *Journal of Experimental Medicine*. 2000, vol 191(1): 33-45. View at publisher, view at Google Scholar, view at scopus
- [24]. A. Gross, J.Jockett, M.C.Weinand, J.Korsmeyer, Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. *The EMBO Journal*, 1998; vol 17(14): 3878-3885. View at publisher, view at Google Scholar, view at scopus

Narmada Thongam. "Thyroid Status Among HIV Infected Cases Attending ART Centre JNIMS And Correlation Between TSH(US) And CD4 Count." *IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)*, vol. 18, no. 8, 2019, pp20-24.